Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
3.400
+0.120 (3.66%)
At close: Jul 3, 2025, 1:00 PM
3.360
-0.040 (-1.18%)
After-hours: Jul 3, 2025, 4:49 PM EDT
Company Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
The company’s clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.
It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Alumis Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Jun 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 170 |
| CEO | Martin Babler |
Contact Details
Address: 280 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 231 6625 |
| Website | alumis.com |
Stock Details
| Ticker Symbol | ALMS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001847367 |
| CUSIP Number | 022307102 |
| ISIN Number | US0223071020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin Babler Ph.D. | President, Chief Executive Officer and Chairman |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Roy C. Hardiman J.D. | Chief Business and Strategy Officer |
| John R. Schroer C.F.A. | Chief Financial Officer |
| Sara Klein | Chief Legal Officer and Corporate Secretary |
| Derrick Richardson | Senior Vice President of People and Culture |
| Claire Langrish Ph.D. | Senior Vice President and Head of Immunology and Translational Science |
| Philip Nunn Ph.D. | Senior Vice President of Pharmacology and Project Team Leader |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer and Head of Research and Development |
| Mark Bradley | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 30, 2025 | 8-K/A | [Amend] Current report |
| Jun 16, 2025 | ARS | Filing |
| Jun 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 16, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 10, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 10, 2025 | SCHEDULE 13D/A | Filing |
| May 23, 2025 | SCHEDULE 13D/A | Filing |
| May 23, 2025 | SCHEDULE 13D/A | Filing |
| May 21, 2025 | 8-K | Current Report |